The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with ...

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on ANI Pharmaceuticals (ANIP – Research Report), ...

ANI Pharmaceuticals (ANIP)  said it completed its planned acquisition of Alimera Sciences (NASDAQ:ALIM). Under the terms of ...

Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a ...

ANI Pharmaceuticals, Inc. ("ANI" or "the Company") (Nasdaq: ANIP) today provided an update on the status of the completion of its previously announced ...

We feel now is a pretty good time to analyse Alimera Sciences, Inc.'s (NASDAQ:ALIM) business as it appears the company may be ...

Alimera Sciences Inc (ALIM) stock saw a modest uptick, ending the day at $5.53 which represents a slight increase of $0.34 or 6.55% from the prior close of $5.19. The stock opened at $5.53 and touched ...

ANI Pharmaceuticals acquiring Alimera Sciences for $5.50 per share with potential for $0.50 per share CVR, offering an ...

ANI Pharmaceuticals (NASDAQ:ANIP) and Alimera Sciences (ALIM) announced that their deal is scheduled to close before the ...

Alimera Sciences files lawsuit against ANI Pharmaceuticals over failed merger, causing stock to plummet 25% in premarket ...

Alimera Sciences, Inc. (ALIM), a biopharmaceutical company, announced on Tuesday that it has filed a lawsuit in the Delaware Court of ...

On June 24, ANI said it was buying Alimera Sciences for $5.50 per share in cash, in a deal that valued Alimera at $381 million. The offer represented a 75% premium to its closing share price of $3.15 ...